118 related articles for article (PubMed ID: 33840435)
1. An International Comparison of EQ-5D-5L and EQ-5D-3L for Use in Cost-Effectiveness Analysis.
Wailoo A; Alava MH; Pudney S; Barton G; O'Dwyer J; Gomes M; Irvine L; Meads D; Sadique Z
Value Health; 2021 Apr; 24(4):568-574. PubMed ID: 33840435
[TBL] [Abstract][Full Text] [Related]
2. Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?
Yang F; Devlin N; Luo N
Value Health; 2019 Jan; 22(1):45-49. PubMed ID: 30661633
[TBL] [Abstract][Full Text] [Related]
3. EQ-5D-5L versus EQ-5D-3L: The Impact on Cost Effectiveness in the United Kingdom.
Hernandez Alava M; Wailoo A; Grimm S; Pudney S; Gomes M; Sadique Z; Meads D; O'Dwyer J; Barton G; Irvine L
Value Health; 2018 Jan; 21(1):49-56. PubMed ID: 29304940
[TBL] [Abstract][Full Text] [Related]
4. Comparing the EQ-5D-5L crosswalks and value sets for England, the Netherlands and Spain: Exploring their impact on cost-utility results.
Ben Â; Finch AP; van Dongen JM; de Wit M; van Dijk SEM; Snoek FJ; Adriaanse MC; van Tulder MW; Bosmans JE
Health Econ; 2020 May; 29(5):640-651. PubMed ID: 32059078
[TBL] [Abstract][Full Text] [Related]
5. Is EQ-5D-5L Better Than EQ-5D-3L? A Head-to-Head Comparison of Descriptive Systems and Value Sets from Seven Countries.
Janssen MF; Bonsel GJ; Luo N
Pharmacoeconomics; 2018 Jun; 36(6):675-697. PubMed ID: 29470821
[TBL] [Abstract][Full Text] [Related]
6. A Comparison of Generic and Condition-Specific Preference-Based Measures Using Data From Nivolumab Trials: EQ-5D-3L, Mapping to the EQ-5D-5L, and European Organisation for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 Dimensions.
Shaw JW; Bennett B; Trigg A; DeRosa M; Taylor F; Kiff C; Ntais D; Noon K; King MT; Cocks K
Value Health; 2021 Nov; 24(11):1651-1659. PubMed ID: 34711366
[TBL] [Abstract][Full Text] [Related]
7. Mapping the kidney disease quality of life 36-item short form survey (KDQOL-36) to the EQ-5D-3L and the EQ-5D-5L in patients undergoing dialysis.
Yang F; Wong CKH; Luo N; Piercy J; Moon R; Jackson J
Eur J Health Econ; 2019 Nov; 20(8):1195-1206. PubMed ID: 31338698
[TBL] [Abstract][Full Text] [Related]
8. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets.
Law EH; Pickard AS; Xie F; Walton SM; Lee TA; Schwartz A
Med Decis Making; 2018 Nov; 38(8):968-982. PubMed ID: 30403577
[TBL] [Abstract][Full Text] [Related]
9. Assessing the Impact of EQ-5D Country-specific Value Sets on Cost-utility Outcomes.
van Dongen JM; Jornada Ben Â; Finch AP; Rossenaar MMM; Biesheuvel-Leliefeld KEM; Apeldoorn AT; Ostelo RWJG; van Tulder MW; van Marwijk HWJ; Bosmans JE
Med Care; 2021 Jan; 59(1):82-90. PubMed ID: 33201085
[TBL] [Abstract][Full Text] [Related]
10. Estimating Cost-Effectiveness Using Alternative Preference-Based Scores and Within-Trial Methods: Exploring the Dynamics of the Quality-Adjusted Life-Year Using the EQ-5D 5-Level Version and Recovering Quality of Life Utility Index.
Franklin M; Hunter RM; Enrique A; Palacios J; Richards D
Value Health; 2022 Jun; 25(6):1018-1029. PubMed ID: 35667775
[TBL] [Abstract][Full Text] [Related]
11. To what extent does the use of crosswalks instead of EQ-5D value sets impact reimbursement decisions?: a simulation study.
Ben ÂJ; van Dongen JM; Finch AP; Alili ME; Bosmans JE
Eur J Health Econ; 2023 Nov; 24(8):1253-1270. PubMed ID: 36371791
[TBL] [Abstract][Full Text] [Related]
12. Is EQ-5D-5L Better Than EQ-5D-3L Over Time? A Head-to-Head Comparison of Responsiveness of Descriptive Systems and Value Sets from Nine Countries.
Janssen MF; Buchholz I; Golicki D; Bonsel GJ
Pharmacoeconomics; 2022 Nov; 40(11):1081-1093. PubMed ID: 35930137
[TBL] [Abstract][Full Text] [Related]
13. Mapping Sri Lankan EQ-5D-3L to EQ-5D-5L Value Sets.
Kularatna S; Chen G; Byrnes J; Scuffham PA
Value Health Reg Issues; 2017 May; 12():20-23. PubMed ID: 28648311
[TBL] [Abstract][Full Text] [Related]
14. Choice Defines QALYs: A US Valuation of the EQ-5D-5L.
Craig BM; Rand K
Med Care; 2018 Jun; 56(6):529-536. PubMed ID: 29668646
[TBL] [Abstract][Full Text] [Related]
15. The Impact of Moving from EQ-5D-3L to -5L in NICE Technology Appraisals.
Pennington B; Hernandez-Alava M; Pudney S; Wailoo A
Pharmacoeconomics; 2019 Jan; 37(1):75-84. PubMed ID: 30094806
[TBL] [Abstract][Full Text] [Related]
16. An evaluation of EQ-5D-3L health utility scores using five country-specific tariffs in a rural population aged 45-69 years in Hua county, Henan province, China.
Wang H; Cao C; Guo C; He Y; Li F; Xu R; Liu M; Liu Z; Pan Y; Liu F; Liu Y; Li J; Cai H; He Z; Ke Y
Health Qual Life Outcomes; 2020 Jul; 18(1):228. PubMed ID: 32660494
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.
Franken MD; de Hond A; Degeling K; Punt CJA; Koopman M; Uyl-de Groot CA; Versteegh MM; van Oijen MGH
Health Qual Life Outcomes; 2020 Jul; 18(1):240. PubMed ID: 32690011
[TBL] [Abstract][Full Text] [Related]
18. Comparing EQ-5D-3L and EQ-5D-5L performance in common cancers: suggestions for instrument choosing.
Zhu J; Yan XX; Liu CC; Wang H; Wang L; Cao SM; Liao XZ; Xi YF; Ji Y; Lei L; Xiao HF; Guan HJ; Wei WQ; Dai M; Chen W; Shi JF
Qual Life Res; 2021 Mar; 30(3):841-854. PubMed ID: 32930993
[TBL] [Abstract][Full Text] [Related]
19. Does linear equating improve prediction in mapping? Crosswalking MacNew onto EQ-5D-5L value sets.
Lamu AN
Eur J Health Econ; 2020 Aug; 21(6):903-915. PubMed ID: 32300999
[TBL] [Abstract][Full Text] [Related]
20. A vision 'bolt-on' increases the responsiveness of EQ-5D: preliminary evidence from a study of cataract surgery.
Gandhi M; Ang M; Teo K; Wong CW; Wei YC; Tan RL; Janssen MF; Luo N
Eur J Health Econ; 2020 Jun; 21(4):501-511. PubMed ID: 31902023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
